Show simple item record

dc.contributor.authorVokes, E
dc.contributor.authorSocinski, M
dc.contributor.authorSpigel, D
dc.contributor.authorPaz-Ares, L
dc.contributor.authorKurek, R
dc.contributor.authorNanda, S
dc.contributor.authorGrau, G
dc.contributor.authorShahidi, J
dc.contributor.authorThatcher, Nick
dc.contributor.authorGandara, D
dc.date.accessioned2017-04-24T14:59:59Z
dc.date.available2017-04-24T14:59:59Z
dc.date.issued2016-10-01
dc.identifier.citationHypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC). 2016, 27(suppl_6):1256P Annals of Oncologyen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdw383.56
dc.identifier.urihttp://hdl.handle.net/10541/620281
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article/2800149/Hypomagnesaemiaen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleHypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDept. of Medicine, The University of Chicago Medical Centre, Chicagoen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record